Passage BIO, Inc. (PASG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 28, 2025, regarding the 2025 Annual Meeting of Stockholders for Passage BIO, Inc., a Delaware corporation and emerging growth company. The company's common stock trades on the Nasdaq Capital Market under the symbol "PASG."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes rather than financial performance.
Material Changes and Voting Results
Three proposals were submitted to and adopted by stockholders at the Annual Meeting:
- Election of Directors: Two Class II directors were elected to three-year terms expiring in 2028:
- Maxine Gowen, Ph.D.: 26,155,123 shares For; 9,920,074 shares Withheld; 13,591,783 Broker Non-Votes.
- Dolan Sondhi, Ph.D.: 26,312,059 shares For; 9,763,138 shares Withheld; 13,591,783 Broker Non-Votes.
- Ratification of Auditors: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes: 49,459,847 For; 70,721 Against; 136,412 Abstaining.
- Authorization of Reverse Stock Split: Stockholders approved an amendment to the Restated Certificate of Incorporation, authorizing the Board to implement a reverse stock split at a ratio between 1-for-5 and 1-for-50.
- Conditions: The exact ratio is at the Board's discretion and must be determined prior to December 31, 2025. The Board retains the authority to abandon the amendment without further stockholder action.
- Votes: 47,038,889 For; 2,324,612 Against; 303,479 Abstaining.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the standard disclosure of the reverse stock split authorization. The primary contingency noted is the Board's discretion to determine the specific split ratio or to abandon the plan entirely before the December 31, 2025 deadline.
Key Facts for Investor Verification
- Verify the specific reverse stock split ratio once determined by the Board, as the current authorization allows for a range of 1-for-5 to 1-for-50.
- Monitor the Board's decision on whether to proceed with or abandon the reverse stock split before the December 31, 2025 deadline.
- Confirm the impact of the newly elected directors (Gowen and Sondhi) on future corporate strategy.
- Note the significant number of broker non-votes (approx. 13.6 million) on the director elections, indicating shares held in street name where brokers lacked discretionary voting power.